3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
22
Leukemia, Myeloid, Acute
21
Lymphoma, Non-Hodgkin
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma
9
Hodgkin Disease
8
Myelodysplastic Syndromes
7
Neoplasms, Plasma Cell
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Leukemia
6
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Gliosarcoma
3
Glioblastoma
3
Sezary Syndrome
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Hairy Cell
2
Hematologic Neoplasms
2
Glioma
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Myeloid
1
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
plerixafor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled